rs199922945
Variant summary
Our verdict is Pathogenic. Variant got 22 ACMG points: 22P and 0B. PVS1PM2PP3_StrongPP5_Very_Strong
The NM_000642.3(AGL):c.1735+1G>T variant causes a splice donor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,613,308 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000642.3 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 22 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
AGL | NM_000642.3 | c.1735+1G>T | splice_donor_variant | ENST00000361915.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
AGL | ENST00000361915.8 | c.1735+1G>T | splice_donor_variant | 1 | NM_000642.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251302Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135824
GnomAD4 exome AF: 0.00000548 AC: 8AN: 1461008Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 726846
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74466
ClinVar
Submissions by phenotype
Glycogen storage disease type III Pathogenic:7
Likely pathogenic, criteria provided, single submitter | clinical testing | Centre for Human Genetics | Aug 27, 2020 | disease causing - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 08, 2024 | This sequence change affects a donor splice site in intron 13 of the AGL gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs199922945, gnomAD 0.01%). Disruption of this splice site has been observed in individuals with glycogen storage disease type III (PMID: 8702417, 29614965). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS G +1 to T. ClinVar contains an entry for this variant (Variation ID: 1100). Studies have shown that disruption of this splice site results in skipping of exon 13 and introduces a premature termination codon (PMID: 8702417). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 25, 2019 | Variant summary: AGL c.1735+1G>T is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: three predict the variant abolishes a 5 splicing donor site; one predicts the variant weakens a 5' donor site. Following cDNA sequence analysis, Okubo_1996 reported this donor splice site variant to result in skipping of the upstream exon causing a premature termination due to frameshift. The variant allele was found at a frequency of 1.2e-05 in 251302 control chromosomes (gnomAD). c.1735+1G>T has been reported in the literature in the compound heterozygous and also homozygous state in multiple individuals affected with Glycogen Storage Disease Type III (Okubo_1996, Lu_2016, Wang_2013). These data indicate that the variant is very likely to be associated with disease. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 22, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 23, 2021 | NM_000642.2(AGL):c.1735+1G>T is a canonical splice variant classified as pathogenic in the context of glycogen storage disease type III. c.1735+1G>T has been observed in cases with relevant disease (PMID: 10982190, 8702417, 32772503). Functional assessments of this variant are available in the literature (PMID: 8702417). c.1735+1G>T has been observed in population frequency databases (gnomAD: EAS 0.02%). In summary, NM_000642.2(AGL):c.1735+1G>T is a canonical splice variant in a gene where loss of function is a known mechanism of disease, is predicted to disrupt protein function, and has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Apr 04, 2020 | - - |
Glycogen storage disease IIIa Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 16, 1996 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at